Revisiting biomarker discovery by plasma proteomics

Molecular Systems Biology

Volumn 13, Issue 9, 2017, Pages

  Geyer, Philipp E ^a,b   Holdt, Lesca M ^c   Teupser, Daniel ^c   Mann, Matthias ^a,b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

biomarkers; diagnostic; mass spectrometry; plasma proteomics; systems medicine

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; PLASMA PROTEIN;

CLINICAL PRACTICE; HUMAN; IMMUNOASSAY; LABORATORY TEST; METABOLOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; STANDARDIZATION; MASS SPECTROMETRY; PHENOTYPE; PROCEDURES;

BIOMARKERS; BLOOD PROTEINS; HUMANS; MASS SPECTROMETRY; PHENOTYPE; PROTEOME; PROTEOMICS;

EID: 85030149063     PISSN: None     EISSN: 17444292     Source Type: Journal    
DOI: 10.15252/msb.20156297     Document Type: Review

References (96)

1. Abbatiello SE, Schilling B, Mani DR, Zimmerman LJ, Hall SC, MacLean B, Albertolle M, Allen S, Burgess M, Cusack MP, Gosh M, Hedrick V, Held JM, Inerowicz HD, Jackson A, Keshishian H, Kinsinger CR, Lyssand J, Makowski L, Mesri M et al (2015) Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics 14: 2357–2374
2. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM et al (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27: 633–641
3. Aebersold R, Mann M (2016) Mass-spectrometric exploration of proteome structure and function. Nature 537: 347–355
4. Altelaar AF, Heck AJ (2012) Trends in ultrasensitive proteomics. Curr Opin Chem Biol 16: 206–213
5. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW (2004) Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 3: 235–244
6. Anderson NL (2010) The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56: 177–185
7. Anderson NL, Ptolemy AS, Rifai N (2013) The riddle of protein diagnostics: future bleak or bright? Clin Chem 59: 194–197
8. Baggerly KA, Morris JS, Coombes KR (2004) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20: 777–785
9. Bantscheff M, Boesche M, Eberhard D, Matthieson T, Sweetman G, Kuster B (2008) Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer. Mol Cell Proteomics 7: 1702–1713
10. Bekker-Jensen DB, Kelstrup CD, Batth TS, Larsen SC, Haldrup C, Bramsen JB, Sørensen KD, Høyer S, Ørntoft TF, Andersen CL, Nielsen ML, Olsen JV (2017) An optimized shotgun strategy for the rapid generation of comprehensive human proteomes. Cell Syst 4: 587–599.e4
11. Bellei E, Bergamini S, Monari E, Fantoni LI, Cuoghi A, Ozben T, Tomasi A (2011) High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids 40: 145–156
12. Bruderer R, Bernhardt OM, Gandhi T, Xuan Y, Sondermann J, Schmidt M, Gomez-Varela D, Reiter L (2017) Heralds of parallel MS: data-independent acquisition surpassing sequential identification of data dependent acquisition in proteomics. Mol Cell Proteomics https://doi.org/10.1074/mcp.M116.065730
13. Burgess MW, Keshishian H, Mani DR, Gillette MA, Carr SA (2014) Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics 13: 1137–1149
14. Cao Z, Tang HY, Wang H, Liu Q, Speicher DW (2012) Systematic comparison of fractionation methods for in-depth analysis of plasma proteomes. J Proteome Res 11: 3090–3100
15. Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, Grant RP, Hoofnagle AN, Huttenhain R, Koomen JM, Liebler DC, Liu T, MacLean B, Mani DR, Mansfield E, Neubert H, Paulovich AG, Reiter L, Vitek O, Aebersold R et al (2014) Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 13: 907–917
16. Cohen Freue GV, Meredith A, Smith D, Bergman A, Sasaki M, Lam KK, Hollander Z, Opushneva N, Takhar M, Lin D, Wilson-McManus J, Balshaw R, Keown PA, Borchers CH, McManus B, Ng RT, McMaster WR, Biomarkers in T, the NCECPoOFCoET (2013) Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput Biol 9: e1002963
17. Cole RN, Ruczinski I, Schulze K, Christian P, Herbrich S, Wu L, Devine LR, O'Meally RN, Shrestha S, Boronina TN, Yager JD, Groopman J, West KP Jr (2013) The plasma proteome identifies expected and novel proteins correlated with micronutrient status in undernourished Nepalese children. J Nutr 143: 1540–1548
18. Cominetti O, Nunez Galindo A, Corthesy J, Oller Moreno S, Irincheeva I, Valsesia A, Astrup A, Saris WH, Hager J, Kussmann M, Dayon L (2016) Proteomic biomarker discovery in 1000 human plasma samples with mass spectrometry. J Proteome Res 15: 389–399
19. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 1367–1372
20. Cox J, Mann M (2011) Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 80: 273–299
21. Demler OV, Pencina MJ, D'Agostino RB Sr (2013) Impact of correlation on predictive ability of biomarkers. Stat Med 32: 4196–4210
22. De-Ritis F, Coltorti M, Giusti G (1957) An enzymic test for the diagnosis of viral hepatitis - the transaminase serum activities. Clin Chim Acta 2: 70–74
23. Duffy MJ, Sturgeon CM, Soletormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM (2015) Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 61: 809–820
24. Ebhardt HA, Root A, Sander C, Aebersold R (2015) Applications of targeted proteomics in systems biology and translational medicine. Proteomics 15: 3193–3208
25. Edfors F, Bostrom T, Forsstrom B, Zeiler M, Johansson H, Lundberg E, Hober S, Lehtio J, Mann M, Uhlen M (2014) Immunoproteomics using polyclonal antibodies and stable isotope-labeled affinity-purified recombinant proteins. Mol Cell Proteomics 13: 1611–1624
26. FDA-NIH: Biomarker-Working-Group (2016) BEST (Biomarkers, EndpointS, and other Tools) resource. Maryland: Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US)
27. Garcia-Bailo B, Brenner DR, Nielsen D, Lee HJ, Domanski D, Kuzyk M, Borchers CH, Badawi A, Karmali MA, El-Sohemy A (2012) Dietary patterns and ethnicity are associated with distinct plasma proteomic groups. Am J Clin Nutr 95: 352–361
28. Geyer PE, Kulak NA, Pichler G, Holdt LM, Teupser D, Mann M (2016a) Plasma proteome profiling to assess human health and disease. Cell Syst 2: 185–195
29. Geyer PE, Wewer Albrechtsen NJ, Tyanova S, Grassl N, Iepsen EW, Lundgren J, Madsbad S, Holst JJ, Torekov SS, Mann M (2016b) Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol Syst Biol 12: 901
30. Grant RP, Hoofnagle AN (2014) From lost in translation to paradise found: enabling protein biomarker method transfer by mass spectrometry. Clin Chem 60: 941–944
31. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR (2013) Breaking a vicious cycle. Sci Transl Med 5: 196cm196
32. Hofmann B, Welch HG (2017) New diagnostic tests: more harm than good. BMJ 358: j3314
33. Holdt LM, Teupser D (2013) From genotype to phenotype in human atherosclerosis–recent findings. Curr Opin Lipidol 24: 410–418
34. Hoofnagle AN, Wener MH (2009) The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 347: 3–11
35. Hoofnagle AN, Whiteaker JR, Carr SA, Kuhn E, Liu T, Massoni SA, Thomas SN, Townsend RR, Zimmerman LJ, Boja E, Chen J, Crimmins DL, Davies SR, Gao Y, Hiltke TR, Ketchum KA, Kinsinger CR, Mesri M, Meyer MR, Qian WJ et al (2016) Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clin Chem 62: 48–69
36. Jennings L, Van Deerlin VM, Gulley ML, College of American Pathologists Molecular Pathology Resource C (2009) Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 133: 743–755
37. Juhasz P, Lynch M, Sethuraman M, Campbell J, Hines W, Paniagua M, Song L, Kulkarni M, Adourian A, Guo Y, Li X, Martin S, Gordon N (2011) Semi-targeted plasma proteomics discovery workflow utilizing two-stage protein depletion and off-line LC-MALDI MS/MS. J Proteome Res 10: 34–45
38. Keshishian H, Burgess MW, Gillette MA, Mertins P, Clauser KR, Mani DR, Kuhn EW, Farrell LA, Gerszten RE, Carr SA (2015) Multiplexed, quantitative workflow for sensitive biomarker discovery in plasma yields novel candidates for early myocardial injury. Mol Cell Proteomics 14: 2375–2393
39. Kim YJ, Sertamo K, Pierrard MA, Mesmin C, Kim SY, Schlesser M, Berchem G, Domon B (2015) Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J Proteome Res 14: 1412–1419
40. Kohler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Ayme S, Baynam G, Bello SM, Boerkoel CF, Boycott KM, Brudno M, Buske OJ, Chinnery PF, Cipriani V, Connell LE, Dawkins HJ, DeMare LE, Devereau AD, de Vries BB, Firth HV et al (2017) The human phenotype ontology in 2017. Nucleic Acids Res 45: D865–D876
41. Kolla V, Jeno P, Moes S, Tercanli S, Lapaire O, Choolani M, Hahn S (2010) Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J Biomed Biotechnol 2010: 952047
42. Lee SE, West KP Jr, Cole RN, Schulze KJ, Christian P, Wu LS, Yager JD, Groopman J, Ruczinski I (2015) Plasma proteome biomarkers of inflammation in school aged children in Nepal. PLoS ONE 10: e0144279
43. Lee SE, Stewart CP, Schulze KJ, Cole RN, Wu LS, Yager JD, Groopman JD, Khatry SK, Adhikari RK, Christian P, West KP Jr (2017) The plasma proteome is associated with anthropometric status of undernourished nepalese school-aged children. J Nutr 147: 304–313
44. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672–683
45. Liu T, Qian WJ, Gritsenko MA, Xiao W, Moldawer LL, Kaushal A, Monroe ME, Varnum SM, Moore RJ, Purvine SO, Maier RV, Davis RW, Tompkins RG, Camp DG II, Smith RD, Inflammation, the Host Response to Injury Large Scale Collaborative Research P (2006) High dynamic range characterization of the trauma patient plasma proteome. Mol Cell Proteomics 5: 1899–1913
46. Liu Y, Buil A, Collins BC, Gillet LC, Blum LC, Cheng LY, Vitek O, Mouritsen J, Lachance G, Spector TD, Dermitzakis ET, Aebersold R (2015) Quantitative variability of 342 plasma proteins in a human twin population. Mol Syst Biol 11: 786
47. Luque-Garcia JL, Neubert TA (2007) Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J Chromatogr A 1153: 259–276
48. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26: 966–968
49. Malmström E, Kilsgard O, Hauri S, Smeds E, Herwald H, Malmstrom L, Malmstrom J (2016) Large-scale inference of protein tissue origin in gram-positive sepsis plasma using quantitative targeted proteomics. Nat Commun 7: 10261
50. Mann M, Kulak NA, Nagaraj N, Cox J (2013) The coming age of complete, accurate, and ubiquitous proteomes. Mol Cell 49: 583–590
51. Manolio TA (2013) Bringing genome-wide association findings into clinical use. Nat Rev Genet 14: 549–558
52. Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M (2017) CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Sci Rep 7: 45477
53. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J et al (2010) Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2: 46ps42
54. Nanjappa V, Thomas JK, Marimuthu A, Muthusamy B, Radhakrishnan A, Sharma R, Ahmad Khan A, Balakrishnan L, Sahasrabuddhe NA, Kumar S, Jhaveri BN, Sheth KV, Kumar Khatana R, Shaw PG, Srikanth SM, Mathur PP, Shankar S, Nagaraja D, Christopher R, Mathivanan S et al (2014) Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res 42: D959–D965
55. Nesvizhskii AI, Vitek O, Aebersold R (2007) Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat Methods 4: 787–797
56. Nie S, Shi T, Fillmore TL, Schepmoes AA, Brewer H, Gao Y, Song E, Wang H, Rodland KD, Qian WJ, Smith RD, Liu T (2017) Deep-dive targeted quantification for ultrasensitive analysis of proteins in non-depleted human blood plasma/serum and tissues. Anal Chem 89: 9139–9146
57. Oberbach A, Schlichting N, Neuhaus J, Kullnick Y, Lehmann S, Heinrich M, Dietrich A, Mohr FW, von Bergen M, Baumann S (2014) Establishing a reliable multiple reaction monitoring-based method for the quantification of obesity-associated comorbidities in serum and adipose tissue requires intensive clinical validation. J Proteome Res 13: 5784–5800
58. Obuchowski NA, Lieber ML, Wians FH Jr (2004) ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 50: 1118–1125
59. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, Kapp EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H et al (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5: 3226–3245
60. Ozcan S, Cooper JD, Lago SG, Kenny D, Rustogi N, Stocki P, Bahn S (2017) Towards reproducible MRM based biomarker discovery using dried blood spots. Sci Rep 7: 45178
61. Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Ziogas A, Anton-Culver H, Brentnall TA (2011) Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 10: 2359–2376
62. Parker CE, Borchers CH (2014) Mass spectrometry based biomarker discovery, verification, and validation–quality assurance and control of protein biomarker assays. Mol Oncol 8: 840–858
63. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P (2008) The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2: 1386–1402
64. Pavlou MP, Diamandis EP, Blasutig IM (2013) The long journey of cancer biomarkers from the bench to the clinic. Clin Chem 59: 147–157
65. Pencina MJ, D'Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48: 1703–1711
66. Percy AJ, Chambers AG, Yang J, Borchers CH (2013) Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. Proteomics 13: 2202–2215
67. Percy AJ, Michaud SA, Jardim A, Sinclair NJ, Zhang S, Mohammed Y, Palmer AL, Hardie DB, Yang J, LeBlanc AM, Borchers CH (2017) Multiplexed MRM-based assays for the quantitation of proteins in mouse plasma and heart tissue. Proteomics https://doi.org/10.1002/pmic.201600097
68. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572–577
69. Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9: 555–566
70. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, Mottaz HM, Varnum SM, Camp DG II, Huang L, Fang X, Zhang WW, Smith RD (2008) Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 7: 1963–1973
71. Rai AJ, Zhang Z, Rosenzweig J, Shih I, Pham T, Fung ET, Sokoll LJ, Chan DW (2002) Proteomic approaches to tumor marker discovery - Identification of biomarkers for ovarian cancer. Arch Pathol Lab Med 126: 1518–1526
72. Razavi M, Leigh Anderson N, Pope ME, Yip R, Pearson TW (2016) High precision quantification of human plasma proteins using the automated SISCAPA Immuno-MS workflow. N Biotechnol 33: 494–502
73. Richards AL, Merrill AE, Coon JJ (2015) Proteome sequencing goes deep. Curr Opin Chem Biol 24: 11–17
74. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24: 971–983
75. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). G Ital Cardiol 17: 831–872
76. Rosenberger G, Bludau I, Schmitt U, Heusel M, Hunter CL, Liu Y, MacCoss MJ, MacLean BX, Nesvizhskii AI, Pedrioli PGA, Reiter L, Röst HL, Tate S, Ting YS, Collins BC, Aebersold R (2017) Statistical control of peptide and protein error rates in large-scale targeted data-independent acquisition analyses. Nat Methods 14: 921–927
77. Rost HL, Rosenberger G, Navarro P, Gillet L, Miladinovic SM, Schubert OT, Wolski W, Collins BC, Malmstrom J, Malmstrom L, Aebersold R (2014) OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data. Nat Biotechnol 32: 219–223
78. Sajic T, Liu Y, Aebersold R (2015) Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin Appl 9: 307–321
79. Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, Kongi K, Cantuti L, Hanisch UK, Philips MA, Rossner MJ, Mann M, Simons M (2015) Cell type- and brain region-resolved mouse brain proteome. Nat Neurosci 18: 1819–1831
80. Shi T, Fillmore TL, Gao Y, Zhao R, He J, Schepmoes AA, Nicora CD, Wu C, Chambers JL, Moore RJ, Kagan J, Srivastava S, Liu AY, Rodland KD, Liu T, Camp DG II, Smith RD, Qian WJ (2013) Long-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis. Anal Chem 85: 9196–9203
81. Skates SJ, Gillette MA, LaBaer J, Carr SA, Anderson L, Liebler DC, Ransohoff D, Rifai N, Kondratovich M, Tezak Z, Mansfield E, Oberg AL, Wright I, Barnes G, Gail M, Mesri M, Kinsinger CR, Rodriguez H, Boja ES (2013) Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res 12: 5383–5394
82. Skol AD, Scott LJ, Abecasis GR, Boehnke M (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209–213
83. Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B, Aebersold R (2011) On the development of plasma protein biomarkers. J Proteome Res 10: 5–16
84. Thulasiraman V, Lin S, Gheorghiu L, Lathrop J, Lomas L, Hammond D, Boschetti E (2005) Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis 26: 3561–3571
85. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJ, Liebler DC (2010) Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 9: 4982–4991
86. Vogeser M, Seger C (2016) Mass spectrometry methods in clinical diagnostics - state of the art and perspectives. Trac-Trends Analyt Chem 84: 1–4
87. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW et al (2011) A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 29: 625–634
88. Wild D (2013) The immunoassay handbook: theory and applications of ligand binding, ELISA, and related techniques, 4th edn. Oxford; Waltham, MA: Elsevier
89. Wu HY, Goan YG, Chang YH, Yang YF, Chang HJ, Cheng PN, Wu CC, Zgoda VG, Chen YJ, Liao PC (2015) Qualification and verification of serological biomarker candidates for lung adenocarcinoma by targeted mass spectrometry. J Proteome Res 14: 3039–3050
90. Zander J, Bruegel M, Kleinhempel A, Becker S, Petros S, Kortz L, Dorow J, Kratzsch J, Baber R, Ceglarek U, Thiery J, Teupser D (2014) Effect of biobanking conditions on short-term stability of biomarkers in human serum and plasma. Clin Chem Lab Med 52: 629–639
91. Zeiler M, Straube WL, Lundberg E, Uhlen M, Mann M (2012) A Protein Epitope Signature Tag (PrEST) library allows SILAC-based absolute quantification and multiplexed determination of protein copy numbers in cell lines. Mol Cell Proteomics 11: O111.009613
92. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882–5890
93. Zhang X, Xiao Z, Liu X, Du L, Wang L, Wang S, Zheng N, Zheng G, Li W, Zhang X, Dong Z, Zhuang X, Wang C (2012) The potential role of ORM2 in the development of colorectal cancer. PLoS ONE 7: e31868
94. Zhang X, Ning Z, Mayne J, Moore JI, Li J, Butcher J, Deeke SA, Chen R, Chiang CK, Wen M, Mack D, Stintzi A, Figeys D (2016) MetaPro-IQ: a universal metaproteomic approach to studying human and mouse gut microbiota. Microbiome 4: 31
95. Zhou C, Simpson KL, Lancashire LJ, Walker MJ, Dawson MJ, Unwin RD, Rembielak A, Price P, West C, Dive C, Whetton AD (2012) Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. J Proteome Res 11: 2103–2113
96. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561–577